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Abstract
Introduction: An adenine insertion polymorphism in the 5' untranslated region
of the endothelin-1 gene is functional and increases the expression of endothe-
lin mRNA and protein in the insertion homozygote. In the present study we
hypothesized that this functional polymorphism might be associated with hyper-
tension and/or orthostatic hypotension.
Material and methods: The adenine insertion polymorphism was genotyped in
381 untreated hypertensive patients and 298 normotensive subjects, all of whom
underwent an upright posture study for orthostatic blood pressure measure-
ments. Orthostatic hypotension was defined as a drop in blood pressure of
20/10 mm Hg or more within 3 min of assuming the upright posture.
Results: The allele frequency of the adenine insertion was similar in hyperten-
sive and normotensive subjects (15.2% vs. 15.3%, p > 0.05). After adjustment
for age, sex and body mass index, blood pressure levels did not differ signifi-
cantly among the genotypes in both hypertensives and normotensives. No asso-
ciations were found between the distribution of the adenine insertion geno-
types and the risk of orthostatic hypotension in both hypertensive patients and
normotensive subjects even after adjustment for demographic parameters and
supine systolic or diastolic blood pressure. Neither hypertensive nor nor-
motensive subjects showed significant differences in orthostatic systolic or dias-
tolic blood pressure changes among the genotype groups (all p > 0.05). 
Conclusions: We concluded that the functional adenine insertion polymorphism
in the endothelin-1 gene is not associated with either hypertension or ortho-
static hypotension risk in Chinese. 
Key words: polymorphism, genotype, blood pressure.
Introduction
Endothelin-1 (ET-1) is one of the most important vasoconstrictor pep-
tides in the human vascular system [1], where it appears to play a funda-
mental role in the maintenance of basal vasomotor tone [2, 3]. The bio-
logical effects of ET-1 are mediated through the activation of two known
ET-1 receptors, ET-A and ET-B [4, 5]. The ET-1 is thought to be involved in
blood pressure (BP) regulation because of the elevated plasma ET-1 levels
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that have been observed in some hypertensive
patients [6] and because of the reported elevated
BP in mice heterozygous for a knockout of the ET-1
gene (Edn1) [7]. In mice, the knockout of collect-
ing duct ET-1 or the combined ET-A and ET-B recep-
tors also caused hypertension on both a normal
and high sodium diet [8, 9]. In normal human sub-
jects, upright tilt did not change arterial pressure
but it did increase the plasma concentrations of 
ET-1 and vasopressin [10, 11]. The increase in plasma
ET-1 concentration was impaired in patients with
autonomic failure [11] as well as in patients with
tilt-induced syncope [12]. Therefore, the EDN1 gene
is a logical candidate to play a role in hypertension
and orthostatic hypotension (OH).
The ET-1 is produced in endothelial cells and is
predominantly secreted toward the adjacent vas-
cular smooth muscle cells, supporting the notion
that endothelins (ETs) are autocrine/paracrine
agents rather than circulating hormones [13]. Ele-
vated ET-1 levels have been found in some but not
all studies of patients with essential hypertension
[14, 15]. Furthermore, increased ET-1 levels are nei-
ther related to BP in hypertensive patients nor do
they induce hypertension in patients with diabetes
[15]. EDN1 mRNA is upregulated by inflammatory
factors and downregulated by nitric oxide (NO),
prostacyclin (PGI2), hypoxia and shear stress [16].
An adenine insertion, located in the 5' untranslat-
ed region (UTR) 138 bp downstream of the tran-
scription start site, is functional and regulates the
expression of EDN1 causing increased mRNA
expression and endothelin protein expression in
insertion homozygotes [17]. This polymorphism has
been associated with orthostatic intolerance [18]
and diastolic BP level in white people [19]. Howev-
er, previous studies have produced inconsistent
results for the association of hypertension with
EDN1 polymorphisms [20, 21] and few data are
available on the association of the adenine inser-
tion polymorphism with OH. We therefore hypoth-
esized that the adenine insertion variant of EDN1
may be associated with increased risk of hyper-
tension and OH in Chinese people. We tested our
hypothesis in 381 untreated hypertensive patients
and 298 normotensive subjects.
Material and methods
Study population
For this study, we recruited 381 unrelated hyper-
tensive patients and 298 normotensive subjects
from Xinyang in Henan Province. To exclude the
effect of antihypertensive drugs on orthostatic BP
regulation, only untreated patients were included
in the study. Hypertensive patients were defined 
as untreated if they were newly diagnosed with
hypertension (systolic BP (SBP)/diastolic BP (DBP) 
≥ 160/95 mm Hg on 3 occasions within 2 months)
and/or if they had been diagnosed as hypertensive
(SBP/DBP ≥ 140/90 mm Hg) in the past but had not
received any antihypertensive drugs for at least 
8 weeks prior to the study. Subjects with systolic
and/or diastolic BP levels < 130/85 mm Hg and no
family history of hypertension were recruited as
normotensive subjects. Subjects were excluded
from the study if they had any known diseases,
including heart failure, secondary hypertension,
Parkinson disease, diabetes mellitus, severe debil-
itating chronic illness (cancer, renal or hepatic dis-
eases), and any history of coronary heart disease
and stroke, and/or if they were currently receiving
antidepressant medications. All subjects underwent
an upright posture study for orthostatic BP meas-
urements. This study was reviewed and approved
by the ethical committees of FuWai Hospital and
local hospitals, and informed consent was obtained
from each subject before they were recruited.
Data collection
Each eligible participant was interviewed in
a community clinic. Anthropometric measurements,
height (m) and weight (kg), and waist and hip cir-
cumference (measured at the umbilicus and the
widest point, respectively), were obtained by trained
researchers. All subjects underwent a standard 
12-lead ECG. Overnight fasting blood was drawn for
assays of fasting blood glucose, blood lipids [total
cholesterol (TC), triglycerides (TG), high-density
lipoprotein cholesterol (HDL-C), low-density lipopro-
tein cholesterol (LDL-C)], serum uric acid and crea-
tinine levels by the core laboratory at FuWai Hos-
pital. Medical history and cigarette smoking and
alcohol consumption status were obtained using
a standardized questionnaire. Obesity was defined
according to World Health Organization criteria as
body mass index (BMI) ≥ 30.0 kg/m2. Metabolic syn-
drome (MS) was determined according to the Inter-
national Diabetes Federation (IDF) criteria of 2005.
Dyslipidemia was diagnosed as any one of the fol-
lowing: TG > 200 mg/dl; TC ≥ 240 mg/dl; LDL-C 
≥ 160 mg/dl; or HDL-C < 40 mg/dl, according to the
Adult Treatment Panel III guideline [22].
Sitting BP was measured by a trained nurse or
physician with a standardized mercury sphygmo-
manometer and appropriate cuff sizes (regular,
large, or thigh) fitted to the subject’s right arm.
Three readings were recorded in a sitting position
at least 30 s apart after more than 5 min of rest,
and three readings on average were analyzed. All
BP investigators had to complete a training pro-
gram on the preparation of study subjects for meas-
uring BP, selection of correct cuff size, and standard
BP measurement technique according to a com-
mon protocol adapted from procedures recom-
mended by the American Heart Association [23].The association of an adenine insertion variant in the 5' UTR of the endothelin-1 gene with hypertension and orthostatic hypotension
Supine and standing BP were recorded with
a mercury sphygmomanometer following a stan-
dardized protocol by a trained physician or nurse.
After a 15-min ECG examination with the partici-
pant lying on an examination table, three supine
measurements of BP and heart rate were recorded
at approximately > 30 s intervals by a trained pro-
fessional. Participants were then asked to rise from
the supine position with the entire forearm relaxed
and supported at heart level on an adjustable table,
and standing measurements were taken at 30 s and
2 min. OH was defined as a decline in SBP of at
least 20 mm Hg and/or a decline in DBP of at least
10 mm Hg either 30 s or 2 min after shifting from
a supine to an upright posture [24].
Genotyping
Genomic DNA was isolated from peripheral
leukocytes. The adenine insertion/deletion poly-
morphism (rs10478694, also described as 4A/3A
polymorphism) 138 bp downstream of the tran-
scription start site in the 5' UTR of EDN1 was detect-
ed by standard polymerase chain reaction (PCR)-
restriction fragment length polymorphism (RFLP)
analysis, gel electrophoresis, and ethidium bromide
staining. All aspects of the DNA source, preparation
and genotyping were controlled using the para-
digms of blindness and randomization. The repro-
ducibility of the genotyping was confirmed by bidi-
rectional sequencing in 100 randomly selected
samples, and was found to be 100%. The primer
sequences used were as follows: forward, 
5'-AGGCGCTGCCTTTTCTCCCCGTTTAA-3' and reverse,
5'-AGCTCCTTGGCAAGCCACAAACAGCA-3'. The resul  -
tant PCR products were digested using the restric-
tion enzyme DraI (New England Biolabs). The geno-
types were 3A/3A, 221 bp; 4A/3A, 197 bp, 221 bp
and 24 bp; and 4A/4A, 197 bp and 24 bp.
Statistical analysis
All of the data were analyzed with SPSS statis-
tical software (version 13.0; SPSS USA Inc). Quan-
titative variables were compared using one-way
analysis of variance (ANOVA), and Tukey’s test or
t-test was used for comparison of the mean values
for pairs of groups. The χ2 test was used for quali-
tative variables, genotype/allele frequencies, and
for the Hardy-Weinberg equilibrium of polymor-
phisms. Stepwise multiple logistic regression analy-
sis was used to assess the contribution of geno-
types to hypertension or OH with adjustment for
age, BMI, supine BP levels, heart rates, fasting blood
glucose and dyslipidemia. The orthostatic BP
changes among genotypes were compared first by
ANOVA or t test, and then by a general linear mod-
el with adjustment for age, sex, BMI, and supine BP
levels. A two-tailed p value of < 0.05 was consid-
ered significant. Assuming an additive model, the
study had more than 80% statistical power to
detect an association (at p = 0.05) with an odds
ratio (OR) of 1.5-1.75 for alleles at 10-20% frequen-
cy, which indicated a low probability of obtaining
a false negative result.
Results
The association of the EDN1 3A/4A 
polymorphism with hypertension risk
Table I summarizes the characteristics of hyper-
tensive patients and normotensive subjects. As
expected, SBP, DBP and most of the other charac-
teristics were higher in hypertensive patients than
in normotensive subjects. The EDN1 3A/4A geno-
types were in Hardy-Weinberg equilibrium in the
hypertensive patients (χ2 = 2.74, p = 0.10) and in
the normotensive subjects (χ2 = 3.29, p = 0.07).
However, no significant differences were found in
the genotype/allele frequencies of the 3A/4A poly-
morphism between hypertensive and normoten-
sive subjects in either the additive, dominant or
recessive models (Table II). After adjustment for age,
BMI, heart rates, fasting blood glucose, plasma
lipids and other conventional risk factors, the asso-
ciation of hypertension with BMI and heart rates
remained statistically significant but the adenine
insertion polymorphism was still not found to be
associated with hypertension risk.
When the systolic and diastolic BP levels were
analyzed separately in hypertensive and nor-
Characteristic Normotensive  Hypertensive  Value of p
controls patients
(n = 298) (n = 381) 
Gender, M/F 107/191 133/248 NS
Age [year] 53.1 ±10.5 55.3 ±8.2 < 0.05
BMI [kg/m2] 24.3 ±3.3 25.9 ±3.5 < 0.05
SBP [mm Hg] 124.0 ±11.8 160.2 ±22.8 < 0.05
DBP [mm Hg] 80.5 ±6.9 98.5 ±11.2 < 0.05
Heart rate  73.8 ±12.2 69.7 ±11.2 < 0.05
[bpm]
HDL-C [mmol/l] 1.50 ±0.31  1.57 ±0.34 < 0.05
LDL-C [mmol/l] 2.65 ±0.81 3.10 ±0.88 < 0.05
TC [mmol/l] 4.97 ±1.02 5.49 ±1.15 < 0.05
FBG [mmol/l] 4.97 ±1.69 5.50 ±1.62 < 0.05
Smoking [%] 20.1 16.5 NS
Drinking [%] 21.8 21.0 NS
BMI – body mass index, SBP – systolic blood pressure, DBP – diastolic
blood pressure, HDL-C – high-density lipoprotein cholesterol, 
LDL-C – low-density lipoprotein cholesterol, TC – total cholesterol, 
FBG – fasting blood glucose, smoking, current and past cigarette smok-
ing; drinking, current and past alcohol drinking
Table I. Clinical characteristics of hypertensive
patients and normotensive controls
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motensive subjects, the results showed that the
hypertensive and normotensive subjects carrying
different 3A/4A genotypes had similar systolic and
diastolic BP levels even after adjustment for age,
sex, and body mass index (Figure 1).
The association of the EDN1 3A/4A 
polymorphism with OH in hypertensive 
and normotensive subjects
Most of the measured characteristics were com-
parable between the patients with and without OH
except that normotensive subjects with OH had sig-
nificantly lower SBP and DBP than those without
OH (Table III). Both hypertensives and normoten-
sives exhibited a similar pattern of BP response to
posture change: higher supine SBP or DBP levels
and lower standing SBP or DBP levels in all subjects
with OH compared to the levels in subjects with-
out OH.
The results in Table IV show that no significant
differences were found in the genotype/allele fre-
quencies of the 3A/4A polymorphism between sub-
jects with and without OH in both hypertensives
and normotensives in the additive, dominant and
recessive models. After adjustment for supine SBP
or DBP levels, heart rates, and conventional risk fac-
tors using a stepwise multiple logistic regression
model, the contribution of the EDN1 adenine inser-
tion allele to the presence of OH remained statis-
tically not significant in the hypertensive and nor-
motensive subjects. A statistically significant
association was found between OH and supine sys-
tolic BP in hypertensive patients (OR 1.03, 95% CI
1.00-1.06, p = 0.049) and in normotensive subjects
(OR 1.04, 95% CI 1.02-1.06, p < 0.001).
We then analyzed the associations between the
EDN1  3A/4A polymorphism and orthostatic
SBP/DBP changes at 30 s and 2 min after standing
as well as supine SBP/DBP in both hypertensive
and normotensive subjects; no association was
found even after adjustment for age, sex, BMI and
supine SBP or DBP using a general linear model
(Table V).
Discussion
In the present study, we investigated the asso-
ciation of the adenine insertion polymorphism in
the 5' UTR of the EDN1 gene with hypertension and
OH risk. After adjustment for age, sex, BMI, and the
other conventional risk factors that were measured,
the EDN1 adenine insertion polymorphism was
found not to be associated with hypertension risk
or with systolic and diastolic BP levels. In both
hypertensive and normotensive subjects, no asso-
*(d/r) p values under dominant/recessive models
Subject N ET1 genotype frequencies n (%)               Allele frequencies n (%) Adjusted OR (95% CI)
3A/3A 3A/4A 4A/4A p (d/r)* 3A 4A p Allele Dominant 
(3A ↔ 4A) model
(3A/4A +
+ 4A/4A ↔
↔ 3A/3A)
Hypertensives 381 278 (73.0) 90 (23.6) 13 (3.4) 0.97 646 (84.8) 116 (15.2) 0.98 1.00 0.99
Normotensives 298 218 (73.2) 69 (23.2) 11 (3.7) (0.95/0.84) 505 (84.7) 91 (15.3) (0.75-1.35) (0.78-1.29)
Table II. ET1 3A/4A genotypes in hypertensive and normotensive subjects
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Figure 1. Mean SBP and DBP levels in individuals carrying EDN1 3A/4A genotypes. Values were adjusted for age, sex
and body mass index using a general linear model. A – Hypertensive patients. B – Normotensive subjects
3A/3A 3A/4A          4A/4AArch Med Sci 2, April / 2012 223
The association of an adenine insertion variant in the 5' UTR of the endothelin-1 gene with hypertension and orthostatic hypotension
ciation was found between the EDN1 3A/4A poly-
morphism and OH or between the EDN1 3A/4A
polymorphism and orthostatic SBP/DBP changes
at 30 s and at 2 min after standing.
The ET-1 is a powerful controller of vasomotor
tone. A recent study reported normal BP in mice
systemically heterozygous for the ET-1 null allele
and decreased BP in endothelial cell-specific ET-1
knockout mice [25]. It has been found that
increased ET-1 activity could impair endothelium-
dependent vasodilator function in hypertensive
patients [26]. These results indicated that ET-1
played an important role in the regulation of BP and
suggested that the functional EDN1 genetic varia-
tion may contribute to the development and varia-
tion of BP . The EDN1 3A/4A polymorphism was
found to be of functional importance for ET-1
expression [17]. It has also been associated with
smoking in hypertensive patients and with less risk
for chronic heart failure [27, 28]. However, the asso-
ciation of the 3A/4A polymorphism with hyperten-
sion needs to be investigated further because the
results from the present study and from previous
studies found no significant difference in the allele
or genotype frequency between the hypertensive
patients and the normotensive controls [21, 28, 29].
In a genome-wide association study, a few loci
(chromosome regions) associated with BP at
a genome-wide level of statistical significance have
been reported [30, 31]. However, no genetic vari-
OH – orthostatic hypotension, BMI – body mass index, SBP – systolic blood pressure, DBP – diastolic blood pressure, MS – metabolic syndrome;
*p < 0.05 patients with OH vs. patients without OH
Characteristics Hypertensive patients Normotensive subjects
With OH Without OH With OH Without OH
N 78 303 72 226
Age [years] 55.6 ±7.9 55.0 ±8.7 51.3 ±10.3 53.5 ±10.9
> 60 years, % (n) 31.0 (24) 27.1 (82) 20.8 (15) 27.9 (63)
Male, % (n) 32.1 (25) 36.0 (109) 37.5 (27) 41.2 (93)
BMI [kg/m2] 26.0 ±3.6 25.9 ±3.4 24.6 ±3.5 24.2 ±3.2
Seated SBP [mm Hg] 162.3 ±20.0 160.6 ±23.1 121.4 ±12.7 124.8 ±11.3*
Seated DBP [mm Hg] 98.6 ±10.9 98.4 ±11.7 78.4 ±7.8 81.1 ±7.5*
HR [bpm] 75.4 ±12.5 73.0 ±12.0 69.1 ±9.3 69.8 ±11.4
Dyslipidemia, % (n) 26.9 (21) 32.0 (97) 23.6 (17) 27.0 (61)
MS, % (n) 21.8 (17) 26.7 (81) 12.5 (9) 12.4 (28)
Obesity, % (n) 16.7 (13) 11.0 (33) 5.6 (4) 4.9 (11)
Supine SBP [mm Hg] 162.9 ±24.8 153.6 ±24.7* 130.0 ±15.3 124.5 ±14.8*
Supine DBP [mm Hg] 99.2 ±15.6 91.9 ±12.3* 83.4 ±10.0 79.2 ±8.7*
Standing SBP at 30 s [mm Hg] 146.5 ±22.3 153.2 ±24.8* 113.4 ±15.3 124.2 ±14.7*
Standing DBP at 30 s [mm Hg] 91.2 ±12.9 96.9 ±12.7* 73.7 ±10.1 81.8 ±9.8*
Standing SBP at 2 min [mm Hg] 146.3 ±22.1 155.4 ±24.6* 114.3 ±15.7 125.3 ±14.8*
Standing DBP at 2 min [mm Hg] 93.7 ±12.7 98.5 ±13.9* 74.6 ±8.6 83.1 ±9.9*
Table III. Clinical characteristics of hypertensive and normotensive subjects with and without OH
*(d/r) p values under dominant/recessive models
Subject N Genotype frequencies n (%) Allele frequencies n (%)
3A/3A 3A/4A 4A/4A p (r/d)* 3A 4A p
Hypertensives 
OH 78 59 (75.6) 15 (19.2) 4 (5.1) 0.42 (0.55/0.35) 133 (85.3) 23 (14.7) 0.85
Non OH 303 219 (72.3) 75 (24.8) 9 (3.0) 513 (84.7) 93 (15.3)
Normotensives 
OH 72 54 (75.0) 16 (22.2) 2 (2.8) 0.86 (0.68/0.64) 124 (86.1) 20 (13.9) 0.60
Non OH 226 164 (72.6) 53 (23.5) 9 (4.0) 381 (84.3) 71 (15.7)
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ants (including the 3A/4A polymorphism) in EDN1
have been reported to be linked with these loci.
OH has been associated with hypertension, dia-
betes mellitus (DM), age, BMI and a number of drugs
[32-34]. The most important compensatory mecha-
nism for short-term orthostatic stress is the influ-
ence of the autonomic nervous system on peripher-
al vascular resistance, heart rate and contractility,
and muscular activity. It has been shown that genes
on chromosome 18q may be responsible for OH [35,
36]. The NEDD4L gene is located just within the locus
proximal to the OH markers on 18q [37] and a func-
tional polymorphism of NEDD4L has been associat-
ed with OH [38]. OH has also been associated with
the G protein α-subunit (GNAS1) T131C polymorphism
and the G protein β subunit (GNB3) C825T polymor-
phism [39]; these G protein subunits are components
of the sympathetic nervous system. In contrast, no
associations have been reported between OH and
polymorphisms in genes encoding the main compo-
nents of the traditional RAS pathway [39, 40]. No
data associating EDN1 polymorphisms with OH are
available. A previous study reported a protective
effect of the EDN1 adenine insertion variant for ortho-
static intolerance, defined as an increase of at least
30 beats per minute in heart rate during upright pos-
ture and/or plasma norepinephrine concentrations
> 600 pg/ml after 30 min of upright posture (or at
the maximal standing tolerance time), and/or the
presence of orthostatic symptoms including dizzi-
ness, lightheadedness, and blurred vision [18]. In con-
trast, a recent study showed that the EDN1 adenine
insertion variant was associated with increased risk
of tilt test-induced vasovagal syncope [41]. In the
present study, we found no association between the
3A/4A polymorphism and OH, consistent with a pre-
vious study that found no association between the
adenine insertion variant and BP levels [18].
The ET-1 induces multiple effects on vascular tone
by binding to two kinds of receptors on endothelial
or smooth muscle cells. The ET-A receptors are high-
ly expressed in vascular smooth muscle cells and
appear to be the major receptor subtype causing
vasoconstriction in human arteries. The ET-B recep-
tors are expressed on both vascular smooth muscle
and endothelial cells. The ET-B receptors on endothe-
lial cells mediate vasodilation by releasing NO and
prostacyclin and they in turn inhibit ET converting
enzyme-1 (ECE-1) expression in endothelial cells and
play an important role in ET-1 clearance [42, 43]. The
infusion of ET-1 into intact rats caused transient
hypotension related to an increase in the produc-
tion of endothelium-derived relaxing factor and
prostacyclin and their release from vascular
endothelial cells [44, 45]. All this evidence suggest-
ed that, in addition to endothelial integrity, the bal-
ance between the distribution of ET-A and ET-B
receptors may determine the ET-1-dependent regu-
lation of vascular tone. Investigations of the asso-
ciation between another EDN1  polymorphism
(Lys198Asn) and BP levels have also produced incon-
sistent results [46-48]. Clearly, further investigations
into the association of the vascular endothelin sys-
tem with BP regulation are needed.
SBP – systolic blood pressure, DBP – diastolic blood pressure, ΔSBP0 – SBP changes at 0 min after standing, ΔSBP2 – SBP changes at 2 min after
standing, ΔDBP0 – DBP changes at 0 min after standing, ΔDBP 2 – DBP changes at or 2 min after standing; p value indicates comparisons between
the genotypes; adjusted p value – p value adjusted for age, sex, body mass index and supine SBP or DBP using a general linear model
Orthostatic BP change Genotypes Value of p Adjusted p
3A/3A 3A/4A  4A/4A
Hypertensive patients n = 278 n = 90 n = 13
Supine SBP 153.6 ±23.9 156.3 ±27.8 160.7 ±26.5 0.86 0.53
Supine DBP 93.1 ±13.4 95.3 ±14.5 94.4 ±11.6 0.96 0.49
ΔSBP0 [mm Hg] –3.6 ±12.4 –3.0 ±12.3 –1.5 ±13.4 0.97 0.84
ΔDBP0 [mm Hg] 2.3 ±8.4 2.1 ±8.3 7.9 ±10.3 0.44 0.15
ΔSBP2 [mm Hg] –2.0 ±12.2 –2.2 ±14.0 –0.4 ±14.1 0.73 0.91
ΔDBP2 [mm Hg] 4.0 ±9.7 4.5 ±9.6 7.0 ±10.5 0.95 0.63
Normotensive subjects n = 218 n = 69 n = 11
Supine SBP 125.7 ±15.2 126.3 ±15.7 122.1 ±9.4 0.40 0.70
Supine DBP 79.9 ±8.9 80.3 ±7.2 82.5 ±6.9 0.93 0.68
ΔSBP0 [mm Hg] –3.4 ±12.6 –4.3 ±12.9 –4.0 ±8.8 0.55 0.89
ΔDBP0 [mm Hg] 0.1 ±8.7 –0.8 ±8.3 –0.4 ±9.5 0.33 0.82
ΔSBP2 [mm Hg] –3.0 ±12.3 –3.8 ±12.4 –3.0 ±12.8 0.63 0.90
ΔDBP2 [mm Hg] 1.1 ±8.3 0.8 ±8.6 0.8 ±9.9 0.44 0.96
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Our study had several strengths that included
the consistent results found in both hypertensive
patients and normotensive subjects for the asso-
ciation of the 3A/4A polymorphism with OH and
orthostatic BP changes, and the exclusion of any
antihypertensive drug effect because only untreat-
ed hypertensive patients were enrolled. A limita-
tion of our study was that the plasma or urine lev-
els of ET-1 were not measured. Previous studies
[13-15, 49] have shown that ETs are autocrine/
paracrine agents rather than circulating hormones,
and plasma levels of ETs have been found to be
poorly correlated with the hypertensive state.
Another limitation of the present study was the
focus on only one functional polymorphism of the
ET-1 gene. Further research is needed to investigate
the association between OH and other polymor-
phisms of the genes that encode the vascular
endothelin system components (ET-1, and the ET-A
and ET-B receptors).
In conclusion, we found no evidence that the
insertion variant in the 5' UTR of the EDN1 was
associated with a genetic predisposition to hyper-
tension and OH risk. Our data suggested that the
role of ET-1 in BP regulation needs to be evaluated
further in future studies.
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